Aducanumab Virtual Symposium at Johns Hopkins University
Open to Everyone
Monday, July 26, 2021
12 - 1 p.m. ET
On June 7, 2021 the FDA approved a new treatment for Alzheimer’s, yet there remains a contentious debate about whether the drug is effective. While this debate rages, millions of people may be eligible for this drug costing $56,000/year which, in one stroke, might double the nation’s spending on prescription drugs. What happens next? The Hopkins Business of Health Initiative and the Hopkins Economics of Alzheimer’s Disease and Services Center have assembled experts to lay the groundwork to inform action steps that would best leverage the opportunities and limit the challenges tied to the approval of aducanumab.
The Hopkins Business of Health Initiative unites the Carey Business School, the Bloomberg School of Public Health, the Johns Hopkins School of Nursing, and the Johns Hopkins School of Medicine around research collaborations to improve the productivity of the nation’s health system to advance a shared vision of a healthier America, supported by an affordable and equitable, high-value healthcare.
The Hopkins’ Economics of Alzheimer’s Disease and Services (HEADS) center is one of the NIH/NIA-funded P30 research centers on the demography & economics of aging and Alzheimer’s disease and Alzheimer’s related dementias (ADRD). The research themes of the heads center are (1) identifying and quantifying the range of ADRD care needs and related economic consequences; and (2) examining how the organization and financing of services affects accessibility, affordability, quality, and equity of ADRD care.
Tradeoffs is a weekly podcast exploring the confusing, costly and often counterintuitive health care system. Combining research and storytelling each week they help people to help folks on main street, wall street and capitol hill have smarter, more honest conversations about health policy. Founder and host, Dan Gorenstein, is the moderator of the symposium. To learn about the show, including their coverage of aducanumab, subscribe here.